PRL and B-cell chronic lymphocytic leukemia: The efficacy of acalabrutinib in an Asian patient population with R/R CLL/SLL was previously demonstrated in a phase 1 Japanese trial [17]; although ORR reached 100% in the trial (CR + PR + PRL), the sample size was small (n = 9), highlighting the need for additional, more robust studies.